In­vivyd re­quests emer­gency use au­tho­riza­tion for Covid-19 pre­ven­tive an­ti­body among im­muno­com­pro­mised

In­vivyd has asked the FDA for an emer­gency use au­tho­riza­tion for its Covid-19 pre-ex­po­sure pre­ven­tion an­ti­body, the Mass­a­chu­setts-based biotech an­nounced Wednes­day.

The com­pa­ny’s mon­o­clon­al an­ti­body is de­signed to pre­vent symp­to­matic Covid-19 among im­muno­com­pro­mised adults and ado­les­cents. Be­cause they have a weak­ened im­mune sys­tem, they don’t typ­i­cal­ly get enough pro­tec­tion from vac­cines. As­traZeneca’s an­ti­body Evusheld was pre­vi­ous­ly au­tho­rized for this pop­u­la­tion, but its EUA was with­drawn in Jan­u­ary 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER